Brief: Geneuro signs agreement with NIH to develop antibody treatment for ALS

Geneuro SA

07/02/2017 17:01

Feb 7 (Reuters) - Geneuro SA  GNRO.PA : 
    * Signs cooperative research and development agreement 
(CRADA) with National Institutes of Health (NIH) to develop 
novel antibody treatment for amyotrophic lateral sclerosis (ALS) 
 
Source text for Eikon:  ID:nBw4gbr38a  
Further company coverage:  GNRO.PA  
 
 (Gdynia Newsroom) 
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))